Literature DB >> 31473559

Efficacy of manganese oxide (Mn2O3) nanoparticles against Leishmania major in vitro and in vivo.

Pooya Tavakoli1, Fatemeh Ghaffarifar2, Hamid Delavari3, Nima Shahpari4.   

Abstract

BACKGROUND: The pentavalent antimonial compounds are the first drug of choice for leishmania infection, but have several side effects that cause some restriction for use. Extension of nanoparticle use in biological research and proven effectiveness of manganese nanoparticles on fungi and bacteria, along with the lack of information about its antileishmanial effects, have motivated this study. Manganese can induce cell apoptosis by increasing FOXO3a-Bim/PUMA mRNA activation and activating of caspase-3 pathway.
METHODS: This study was aimed to examine the efficacy of manganese oxide nanoparticles againstLeishmania major (MRHO/IR/75/ER) in vitro and in vivo. To evaluate the antileishmanial activity of NPs, light microscopic observation was used to determine the number of remaining parasites in each well. The MTT test was used to determine the cytotoxicity effects of Mn2O3 NPs against L. major promastigotes and macrophage cells. The effect of nanoparticles on cultured amastigotes under in vitro conditions was also investigated. The possible apoptosis of L. major by Mn2O3 NPs was evaluated with flow cytometry assay. Additionally, the preventive and therapeutic effects of Mn2O3 NPs in BALB/c mice following cutaneous L. major infection was tested. The effect of Mn2O3 NPs on promastigotes and amastigotes were proven by MTT assay and amastigote assay, respectively.
RESULTS: The IC50 value of Mn2O3 NPs against L. major promastigotes and macrophages was 15 and 40 μg ml-1 respectively. The results of flow cytometry showed about 57% of the promastigotes were induced to apoptosis with Mn2O3 NPs. In in vivo studies, the size of the ulcers were significantly reduced, and the survival rate of the mice, in comparison with the control group, was increased.
CONCLUSION: Mn2O3 NPs has a beneficial effect on L. major promastigotes in vitro and in vivo and could be considered as a candidate for the treatment of this infection.
Copyright © 2019 Elsevier GmbH. All rights reserved.

Entities:  

Keywords:  BALB/c; In vitro; In vivo; Leishmania major; Mn(2)O(3) NPs

Year:  2019        PMID: 31473559     DOI: 10.1016/j.jtemb.2019.08.003

Source DB:  PubMed          Journal:  J Trace Elem Med Biol        ISSN: 0946-672X            Impact factor:   3.849


  3 in total

Review 1.  Nanotechnology based solutions for anti-leishmanial impediments: a detailed insight.

Authors:  Humzah Jamshaid; Fakhar Ud Din; Gul Majid Khan
Journal:  J Nanobiotechnology       Date:  2021-04-15       Impact factor: 10.435

2.  Fe3O4@Bio-MOF Nanoparticles Combined with Artemisinin, Glucantime®, or Shark Cartilage Extract on Iranian Strain of Leishmania major (MRHO/IR/75/ER): An In-Vitro and In-Vivo Study.

Authors:  Fatemeh Ghafarifar; Soheila Molaie; Reza Abazari; Zoheir-Mohammad Hasan; Masoud Foroutan
Journal:  Iran J Parasitol       Date:  2020 Oct-Dec       Impact factor: 1.012

3.  Synthesis of Tellurium Oxide (TeO2) Nanorods and Nanoflakes and Evaluation of Its Efficacy Against Leishmania major In Vitro and In Vivo.

Authors:  Pooya Tavakoli; Fatemeh Ghaffarifar; Hamid Delavari; Amir KarimiPourSaryazdi; Mohammad Saaid Dayer; Vahid Nasiri; Salimeh Ahmadi
Journal:  Acta Parasitol       Date:  2021-06-26       Impact factor: 1.440

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.